Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Cutsem on Challenges of Targeted Therapies in Gastric Cancer

January 15th 2015

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.

FOLFOXIRI Plus Bevacizumab Superior as Frontline mCRC Regimen

January 12th 2015

Intensifying the chemotherapy component of a standard first-line bevacizumab-containing regimen reduced the risk of death by about 20% and doubled the 5-year overall survival (OS) rate among patients with metastatic colorectal cancer (mCRC).

Surveillance Could Be a Viable Option for Select Patients With Rectal Cancer

January 12th 2015

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

Higher Vitamin D Levels Improve Survival for Patients With mCRC

January 12th 2015

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Ramucirumab Improves Survival in Second-Line mCRC

January 12th 2015

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

Dr. Abou-Alfa Discusses CRP in HCC

February 18th 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment

Dr. Ramanathan on an Analysis of the MPACT Trial

February 11th 2014

Ramesh K. Ramanathan, MD, medical director, Clinical Trials Program, Virginia G. Piper Cancer Center, describes the results from an analysis of metabolic response by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from the phase III MPACT trial.

Dr. Kunz on Treatment Options for Pancreatic NETs

February 10th 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses current and future treatment options for patients with neuroendocrine tumors (NETs).

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Dr. Abou-Alfa on LY2157299 in HCC

January 28th 2014

Ghassan K. Abou-Alfa, MD, discusses the phase II study of a novel transforming growth factor-beta (TGF-Î²1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Dr. Bordonaro on First-Line Treatment Options for mCRC

January 24th 2014

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Novel Targeted Agent Leads to Survival Benefit in HCC

January 20th 2014

Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer

January 20th 2014

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Dr. Ramanathan on Biomarkers in Appendix Cancer

January 20th 2014

Ramesh K. Ramanathan, MD, discusses the potential of identifying actionable targets in appendiceal cancers.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Dr. Fine on Capecitabine Plus Temozolomide for NETs

January 17th 2014

Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.

Dr. Smitha Krishnamurthi on the Phase III RAINBOW Trial

January 17th 2014

Smitha Krishnamurthi, MD, discusses the results of the RAINBOW TRIAL

High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors

January 14th 2014

Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.